Payment overview · 2025
General Payments
$5,100.66
260 reported records · 34 companies
Healthcare provider profile · identity verified
Peter Alan Tarbox, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SAN ANTONIO, TX · NPI 1063472678
Verified facts
What the public records show
CMS Open Payments records show Peter Alan Tarbox, M.D. received $5,100.66 in general payments during 2025 across 260 reported records.
UCB, Inc. accounted for 13.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ampyra, Austedo Xr, Briviact, Epidiolex, Fycompa, Gamunex-C, Ingrezza, Nayzilam, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Ubrelvy, Valtoco, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rytary by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Fycompa by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gamunex-C by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Epidiolex by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xadago as an associated drug or biological on 139 records involving 79 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xadago by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ampyra by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Valtoco by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Panzyga by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo Xr by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $702.92 | 13.8% | 21 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $461.61 | 9.1% | 22 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $366.86 | 7.2% | 23 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $330.95 | 6.5% | 20 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $318.20 | 6.2% | 18 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$283.65 | 5.6% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $229.32 | 4.5% | 12 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $197.46 | 3.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $176.70 | 3.5% | 26 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $174.79 | 3.4% | 8 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $159.51 | 3.1% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $151.24 | 3.0% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $146.76 | 2.9% | 10 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $144.70 | 2.8% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $120.85 | 2.4% | 5 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $117.34 | 2.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $117.18 | 2.3% | 6 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $109.45 | 2.1% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $108.98 | 2.1% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $108.85 | 2.1% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $72.27 | 1.4% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $67.61 | 1.3% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.56 | 1.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.49 | 1.1% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $46.44 | 0.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.63 | 0.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $42.44 | 0.8% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.01 | 0.8% | 5 | 2025 |
| Otter Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $36.92 | 0.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.26 | 0.6% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.91 | 0.5% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $20.36 | 0.4% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $16.87 | 0.3% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $16.57 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,100.66 | 260 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $461.61 | 22 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $330.17 | 18 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $319.53 | 16 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $318.20 | 18 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $283.65 | 10 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $250.66 | 12 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $233.27 | 5 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $229.32 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $197.47 | 14 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $197.46 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $182.61 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $174.79 | 8 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $159.51 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $151.24 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $146.76 | 10 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $144.70 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.45 | 21 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $120.85 | 5 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $115.06 | 4 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $109.45 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $108.85 | 4 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $105.77 | 5 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $72.27 | 3 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $70.35 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $67.61 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $66.21 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $57.56 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $56.49 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.94 | 9 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $46.44 | 3 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $42.63 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.63 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $42.44 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $39.01 | 5 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $38.84 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| SYMPAZAN Normalized: sympazan |
Drug | Otter Pharmaceuticals, LLC | $36.92 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $9.26 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AMPYRA ampyra |
2025 | Ampyra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 63 | exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 70 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 59 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 40 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 52 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Xadago open payments reported associated product |
CMS Open Payments — General Payments 139 supporting records · 79 recipient NPIs · example record 1241843808 |
Xadago · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
59 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 630 | 204 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 503 | 140 |
| Memantine Hcl | Memantine Hcl | 443 | 119 |
| Gabapentin | Gabapentin | 364 | 107 |
| Levetiracetam | Levetiracetam | 321 | 83 |
| Lacosamide | Lacosamide | 244 | 41 |
| Topiramate | Topiramate | 187 | 42 |
| Clonazepam | Clonazepam | 178 | 39 |
| Aimovig Autoinjector | Erenumab-Aooe | 128 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 21 |
| Alprazolam | Alprazolam | 110 | 20 |
| Oxcarbazepine | Oxcarbazepine | 104 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 23 |
| Lamotrigine | Lamotrigine | 96 | 17 |
| Lorazepam | Lorazepam | 96 | 25 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 95 | 28 |
| Pregabalin | Pregabalin | 91 | 37 |
| Propranolol Hcl | Propranolol Hcl | 90 | 30 |
| Rivastigmine | Rivastigmine | 83 | 26 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 81 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 74 | 32 |
| Zonisamide | Zonisamide | 74 | 16 |
| Nuplazid | Pimavanserin Tartrate | 70 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 16 |
| Primidone | Primidone | 64 | 19 |
| Tramadol Hcl | Tramadol Hcl | 64 | 14 |
| Ingrezza | Valbenazine Tosylate | 63 | 11 |
| Rytary | Carbidopa/Levodopa | 63 | 14 |
| Epidiolex | Cannabidiol (Cbd) | 61 | suppressed |
| Amantadine | Amantadine Hcl | 60 | 14 |
| Nurtec Odt | Rimegepant Sulfate | 59 | 22 |
| Trazodone Hcl | Trazodone Hcl | 58 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 57 | 20 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 57 | suppressed |
| Rexulti | Brexpiprazole | 52 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 51 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 14 |
| Baclofen | Baclofen | 49 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Divalproex Sodium | Divalproex Sodium | 45 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 41 | 13 |
| Memantine Hcl Er | Memantine Hcl | 40 | 12 |
| Qulipta | Atogepant | 40 | 16 |
| Austedo | Deutetrabenazine | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | 12 |
| Fycompa | Perampanel | 36 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 36 | suppressed |
| Xcopri | Cenobamate | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 30 | suppressed |
| Neupro | Rotigotine | 28 | suppressed |
| Ubrelvy | Ubrogepant | 27 | suppressed |
| Levetiracetam Er | Levetiracetam | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 23 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Briviact | Brivaracetam | 19 | suppressed |
| Dalfampridine Er | Dalfampridine | 19 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Droxidopa | Droxidopa | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Austedo Xr | Deutetrabenazine | 17 | suppressed |
| Clobazam | Clobazam | 17 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 17 | suppressed |
| Valtoco | Diazepam | 17 | suppressed |
| Kesimpta Pen | Ofatumumab | 16 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 15 | suppressed |
| Lamictal | Lamotrigine | 15 | suppressed |
| Adlarity | Donepezil Hcl | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | 14 |
| Horizant | Gabapentin Enacarbil | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nayzilam | Midazolam | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Ampyra | Dalfampridine | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Vimpat | Lacosamide | 12 | suppressed |
| Xadago | Safinamide Mesylate | 12 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 11 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Vumerity | Diroximel Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,100.66 · 260 records | UCB, Inc. | AMPYRA, AMYVID, AUSTEDO XR, BRIUMVI, Briviact, CREXONT, EPIDIOLEX, FIRDAPSE, FYCOMPA, Fintepla, Gamunex-C, Gocovri, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, QUTENZA, REXULTI, Rystiggo, SYMPAZAN, Senza, TYSABRI, UBRELVY, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, ZEPOSIA, Zilbrysq | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ampyra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error